Skip to main content

Advertisement

Table 1 Baseline demographic and clinical data concerning the study cohort

From: Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study

Total number of patients 20
Age (years)a 61 (36–85)
Sex
 Female 11 (55)
 Male 9 (45)
Relationship status
 Married 9 (45)
 Cohabiting 3 (15)
 Single 8 (40)
Children
 Yes 16 (80)
 No 4 (20)
Time since primary diagnosis (years)a 8 (2–22)
Time receiving systemic treatment (years)a 6 (2–15)
Primary tumour localisation
 Stomach 12 (60)
 Small bowel 7 (35)
 Rectum 1 (5)
KIT/PDGFRA mutations
 KIT exon 11 11 (55)
 KIT exon 9 3 (15)
 KIT exon 13 1 (5)
 PDGFRA exon 18 1 (5)
 PDGFRA exon 12 1 (5)
 Not detected 3 (15)
Metastatic site
 Liver 10 (50)
 Peritoneal 8 (40)
 Liver and peritoneal 2 (10)
Metastasis at diagnosis
 Yes 10 (50)
 No 10 (50)
Previous adjuvant imatinib treatment (12–36 months)
 Yes 5 (25)
 No 15 (75)
Systemic treatment in a metastatic setting
 Imatinib 18 (90)
 Sunitinib 2 (10)
Number of surgeries (including surgery to the primary tumour)
 No surgery 1 (5)
 1 10 (50)
 2 8 (40)
 5 1 (5)
Radiotherapy
 Yes 2 (10)
 No 18 (90)
  1. The values given in parentheses are percentages unless otherwise indicated, avalues are the median (range)
  2. PDGFRA platelet-derived growth factor α-gene